Omnicell provides medication management and pharmacy automation solutions to healthcare systems, hospitals, and pharmacies across the United States and internationally. The company's core offerings include automated dispensing systems for clinical areas, central pharmacy dispensing services, and IV compounding services. Its XT Series represents its primary point-of-care automation platform designed to enhance clinician workflows and medication safety in nursing units and other hospital departments.
Beyond automation hardware, Omnicell operates several complementary business segments. The company manages specialty pharmacy services on behalf of health systems, handling payer contracting, staffing, licensing, and 340B program administration. It also delivers medication adherence solutions through single-dose automation, blister card packaging systems, and software-guided manual filling processes. Additionally, Omnicell provides inventory optimization services utilizing predictive analytics, benchmarking tools, and medication visibility platforms, alongside patient engagement and clinical decision-support software.
The company supports its customer base through professional services including installation, training, and change management, as well as ongoing technical support and maintenance. Omnicell maintains international operations through retail pharmacy and hospital automation businesses outside North America. Incorporated in Delaware in 1992 and headquartered in Fort Worth, Texas, the company operates with a distributed workforce supporting its diverse customer base across multiple care settings and geographies.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $0.04 | $0.04 | -85.2% | |
| 2024 | $0.27 | $0.27 | +160.0% | |
| 2023 | $-0.45 | $-0.45 | -475.0% | |
| 2022 | $0.12 | $0.13 | -92.6% | |
| 2021 | $1.62 | $1.79 | +118.9% | |
| 2020 | $0.74 | $0.76 | -48.3% | |
| 2019 | $1.43 | $1.48 | +53.8% | |
| 2018 | $0.93 | $0.96 | +75.5% | |
| 2017 | $0.53 | $0.55 | +2550.0% | |
| 2016 | $0.02 | $0.02 | -97.6% | |
| 2015 | $0.84 | $0.86 | +1.2% | |
| 2014 | $0.83 | $0.86 | +23.9% | |
| 2013 | $0.67 | $0.69 | +42.6% | |
| 2012 | $0.47 | $0.49 | +56.7% | |
| 2011 | $0.30 | $0.31 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0000926326-26-000006 | SEC ↗ |
| 2024-12-31 | 2025-02-27 | 0000926326-25-000003 | SEC ↗ |
| 2023-12-31 | 2024-02-28 | 0000926326-24-000008 | SEC ↗ |
| 2022-12-31 | 2023-03-01 | 0000926326-23-000003 | SEC ↗ |
| 2021-12-31 | 2022-02-25 | 0000926326-22-000007 | SEC ↗ |
| 2020-12-31 | 2021-02-24 | 0000926326-21-000007 | SEC ↗ |
| 2019-12-31 | 2020-02-26 | 0000926326-20-000010 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0000926326-19-000007 | SEC ↗ |
| 2017-12-31 | 2018-02-27 | 0000926326-18-000010 | SEC ↗ |
| 2016-12-31 | 2017-02-28 | 0000926326-17-000015 | SEC ↗ |
| 2015-12-31 | 2016-02-26 | 0000926326-16-000044 | SEC ↗ |
| 2014-12-31 | 2015-03-30 | 0000926326-15-000012 | SEC ↗ |
| 2013-12-31 | 2014-03-17 | 0000926326-14-000005 | SEC ↗ |